Literature DB >> 21480857

Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.

Anton B Alexandroff, Volha Shpadaruk, W Mark Bamford, D Ben J Kennedy, Robert Burd, Martin J S Dyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21480857     DOI： 10.1111/j.1365-2141.2011.08620.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

1.  Mutation in PIGA results in a CD52-negative escape variant in a Sézary syndrome patient during alemtuzumab treatment.

Authors:  Constantijn J M Halkes; Willem H Zoutman; Leslie van der Fits; Inge Jedema; Maarten H Vermeer
Journal:  J Invest Dermatol       Date:  2014-11-28       Impact factor: 8.551

2.  Syntheses and anti-HIV and human cluster of differentiation 4 (CD4) down-modulating potencies of pyridine-fused cyclotriazadisulfonamide (CADA) compounds.

Authors:  Liezel A Lumangtad; Elisa Claeys; Sunil Hamal; Amarawan Intasiri; Courtney Basrai; Expedite Yen-Pon; Davison Beenfeldt; Kurt Vermeire; Thomas W Bell
Journal:  Bioorg Med Chem       Date:  2020-10-26       Impact factor: 3.641
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.